Pharmacoeconomic evaluation of ribociclib as first-line treatment in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
ZHANG Sen, WANG Jie, LI Sai-nan, WANG Mei-qi, JU Ying-bo, WANG Ming-xia, JIA Cai-feng
Chinese Journal of New Drugs . 2025, (16): 1784 -1792 .  DOI: 10.20251/j.cnki.1003-3734.2025.16.014

Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.